Edgewise Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Edgewise Therapeutics, Inc. (EWTX) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-133.81-100.16-67.64-42.81-17.12
Depreciation & Amortization2.291.730.030.300.19
Stock Based Compensation24.7117.5610.924.400.35
Change in Working Capital10.33-1.56-0.073.011.95
Change in Accounts Payable1.74-0.090.052.650.52
Change in Other Working Capital8.59-1.474.041.981.43
Other Operating Activities-12.557.9413.844.400.00
Net Cash from Operating Activities-109.03-91.95-52.64-33.51-14.63
Investing Activities
Capital Expenditures-1.31-5.755.550.67-0.20
Purchases of Investments-183.34-255.87-292.39-288.20-24.18
Sales/Maturities of Investments293.71364.50-65.03-241.560.00
Other Investing Activities0.0020.1230.573.440.00
Net Cash from Investing Activities-184.66102.89-70.58-242.23-24.38
Financing Activities
Debt Repayment0.000.00-0.250.000.00
Common Stock Issued249.5252.62129.49186.400.20
Other Financing Activities-0.26-0.17-0.25-0.120.00
Net Cash from Financing Activities249.2553.17129.64186.38120.28
Summary
Net Change in Cash-44.4364.106.43-89.3581.26
Cash at Beginning of Period86.1021.9915.57104.920.00
Cash at End of Period41.6786.1021.9915.570.00
Free Cash Flow-110.34-97.69-58.18-34.18-14.84